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production and -degradation is necessary to prevent pathological Aβ-accumulation. 
Here,	we	investigate	the	molecular	mechanism	how	insulin-degrading	enzyme	(IDE),	




protein	 level,	and	expression.	Similar	 results	were	obtained	 in	cells	only	expressing	
a	 truncated	APP,	 lacking	the	APP	 intracellular	domain	 (AICD)	suggesting	that	AICD	
promotes IDE	expression.	 In	return,	APP overexpression mediated an increased IDE 
expression,	comparable	results	were	obtained	with	cells	overexpressing	C50,	a	trun-
cated	 APP	 representing	 AICD.	 Beside	 these	 genetic	 approaches,	 also	 AICD	 pep-
tide incubation and pharmacological inhibition of the γ-secretase	 preventing	AICD	
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1  |  INTRODUC TION
Currently,	 more	 than	 50	 million	 people	 globally	 are	 estimated	 to	
suffer	 from	 dementia.	 Alzheimer’s	 disease	 (AD)	 is	 a	 progressive,	
irreversible neurodegenerative disease which is the most common 
cause of dementia in the elderly. The excessive accumulation and 
aggregation of the amyloid-β	(Aβ)	peptide	in	brain	tissue	leading	to	
the	 formation	of	 extracellular	 senile	plaques	 is	 considered	 to	 rep-
resent	 the	 initial	pathological	process	of	 the	disease	characterized	
by	synaptic	loss	and	neuronal	injury	(Chen	et	al.,	2017).	Aβ peptides 
are	 products	 of	 the	 sequential	 amyloidogenic	 processing	 of	 the	
type	 I	 transmembrane	amyloid	precursor	protein	 (APP),	a	member	
of	a	conserved	protein	family	also	including	the	APP-like	proteins	1	
and	2	(APLP1	and	APLP2),	by	β- and γ-secretase	(Figure	S1).	Beside	
the amyloidogenic APP processing pathway, APP can be cleaved 
in the predominant α- and γ-secretase dependent non-amyloi-
dogenic cleavage cascade precluding the generation of Aβ peptides. 
In	both	APP	processing	pathways,	cleavage	of	APP	by	γ-secretase 
additionally	leads	to	the	release	of	the	C-terminal	APP	intracellular	
domain	 (AICD)	 into	 the	 cytosol.	Due	 to	multiple-site	 cleavages	by	
γ-secretase, Aβ	and	AICD	peptides	can	vary	in	length	with	the	main	
products being Aβ38, Aβ40, Aβ42,	and	AICD	C50,	C53,	C57,	C59,	
respectively	(Chen	et	al.,	2017;	Grimm	et	al.,	2013).
Total cerebral Aβ level is not only determined by Aβ-production, 
but also by Aβ-clearance and degradation mechanisms, which have 
been reported to be impaired in the predominant late onset form 
of	AD	(Mawuenyega	et	al.,	2010).	These	Aβ-clearance mechanisms 
include	among	others	the	enzymatic	elimination	of	Aβ peptides by 
proteases	 like	 insulin-degrading	enzyme	(IDE)	and	neprilysin	 (NEP)	
(Nalivaeva	 &	 Turner,	 2019).	 IDE	 is	 a	 zinc	 metallopeptidase	 most	
abundant in the cytosol, but also in several other subcellular com-
partments	(Saido	&	Leissring,	2012)	and	represents	one	of	the	most	
important Aβ-degrading	enzymes	in	brain	tissue.	IDE	deficient	mice	






has been reported to be involved in the transcriptional regulation of 
several target genes including APP, BACE1, NEP,	key	enzymes	of	dif-
ferent lipid pathways and the mitochondrial master transcriptional 







which	 functions	 in	 transcriptional	 regulation,	 is	 formed	 (Cao	 &	
Sudhof,	2001;	von	Rotz	et	al.,	2004).




proteolytic APP processing generates Aβ peptides and concurrently 
ensures	their	enzymatic	degradation.
2  |  RESULTS
2.1  |  Total Aβ-degradation is reduced in MEF cells 
devoid of PS1/2, APP/APLP2, and AICD
In	order	to	analyze	the	impact	of	the	catalytically	active	subunit	of	
the γ-secretase	complex,	 the	presenilins	 (PS),	on	 total	 intracellular	
Aβ-degrading	activity	we	used	mouse	embryonic	fibroblasts	(MEFs)	
devoid	of	PS1	and	PS2	(MEF	PS1/2−/−)	and	PS1	retransfected	con-
trol	 cells	 (MEF	PS1res)	 to	avoid	clonal	heterogeneity	 (Figure	S2A).	
Total intracellular Aβ-degradation was measured by the addition 
of synthetic human Aβ40 peptides to the cell lysates for 1 h and 
subsequent	 quantification	 of	 the	 remaining,	 not	 degraded	 human	
Aβ40. No significant difference in Aβ-degradation was observed 
between	 MEF	 wild	 type	 (MEF	 WT)	 and	 MEF	 PS1res	 (Figure	 1a,	
production regulated IDE	expression	and	promoter	activity.	By	utilizing	CRISPR/Cas9	
APP	and	Presenilin	knockout	SH-SY5Y	cells	results	were	confirmed	in	a	second	cell	
line	in	addition	to	mouse	embryonic	fibroblasts.	In	vivo,	IDE expression was decreased 
in	mouse	brains	devoid	of	APP	or	AICD,	which	was	in	line	with	a	significant	correla-
tion of APP expression level and IDE expression in human postmortem	AD	brains.	Our	
results	show	a	tight	link	between	Aβ-production and Aβ-degradation forming a regu-
latory	cycle	in	which	AICD	promotes	Aβ-degradation	via	IDE	and	IDE	itself	limits	its	
own	production	by	degrading	AICD.
K E Y W O R D S
Alzheimer's	disease,	APP	intracellular	domain,	Aβ homeostasis, Aβ-degradation, insulin-
degrading	enzyme
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Table	 1).	 Considering	 the	 known	 AICD-dependent	 transcriptional	
regulation of NEP	(Grimm	et	al.,	2015),	total	Aβ-degradation was sig-
nificantly	reduced	in	MEF	PS1/2−/−	compared	to	MEF	PS1res	cells	
since remaining human Aβ peptides were significantly increased 
to	120.5%	in	PS1/2−/−	cells	(Figure	1a,	Table	1).	The	magnitude	of	
effect	 of	 PS1/2-deficiency	 on	 total	 Aβ-degradation was less pro-
nounced	 after	 transient	 IDE	 knockdown	 (knockdown	 efficiency	
56%,	 see	 Figure	 S2B)	 (remaining	Aβ	 in	MEF	PS1/2−/−	 IDE	 knock-
down: 113.0% ± 9.1%, p	=	0.339)	(Figure	1b)	compared	to	the	same	
experiment	where	 IDE	was	not	knocked	down.	This	 indicates	 that	
besides	NEP	IDE	might	also	be	affected	by	a	lack	of	γ-secretase ac-
tivity. Besides APP more than 90 other substrates processed by the 
γ-secretase	complex	have	been	identified	(Wolfe,	2020).	Therefore,	
we	 elucidated	whether	 the	 effect	 of	 PS1/PS2-deficiency	 on	 total	
Aβ-degrading activity is depending on APP and its γ-secretase de-
pendent cleavage products Aβ	and	AICD.	Aβ-degradation was meas-














AICD	domain	(MEF	APPΔCT15)	compared	to	MEF	WT.	(a–c)	Total	Aβ-degradation was determined by addition of human synthetic Aβ40 
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TA B L E  1 Overview	of	results	shown	in	Figures	1–6.	Mean	±	SEM and p-value
p-Value
Figure 1 Total Aβ-degradation: remaining Aβ
A MEF	PS1res	(100%)	vs.	MEF	WT 103.5% ± 3.7% 0.526
MEF	PS1res	(100%)	vs.	MEF	PS1/2−/− 120.5% ± 3.2% 0.000
B MEF	PS1res	+	IDE-KD	(100%)	vs.	MEF	PS1/2−/−	+	IDE-KD 113.0% ± 9.1% 0.339
C MEF	WT	(100%)	vs.	MEF	APP/APLP2−/− 143.0% ±6.3% 0.000
MEF	WT	(100%)	vs.	MEF	APPΔCT15 151.5% ±8.2% 0.000
Figure 2 IDE	activity
A MEF	PS1res	(100%)	vs.	MEF	PS1/2−/− 88.5% ± 2.5% 0.019
B MEF	WT	(100%)	vs.	MEF	APP/APLP2−/− 82.6% ± 1.7% 0.005
MEF	WT	(100%)	vs.	MEF	APPΔCT15 73.9% ± 4.9% 0.002
IDE	protein	level
C MEF	PS1res	(100%)	vs.	MEF	PS1/2−/− 69.8% ± 3.8% 0.000
MEF	PS1res	(100%)	vs.	PS1res	+	DAPT 68.7% ± 5.9% 0.000
D MEF	WT	(100%)	vs.	MEF	APP/APLP2−/− 41.4% ± 4.2% 0.000
MEF	WT	(100%)	vs.	MEF	APPΔCT15 59.3% ± 10.4% 0.007
Figure 3 IDE	gene	expression
A MEF	PS1res	(100%)	vs.	MEF	PS1/2−/− 74.7% ± 7.2% 0.010
B MEF	WT	(100%)	vs.	MEF	APP/APLP2−/− 76.6% ± 6.4% 0.000
MEF	WT	(100%)	vs.	MEF	APPΔCT15 37.9% ± 9.7% 0.001
C SH-SY5Y	WT	(100%)	vs.	SH-SY5Y	PS1−/− 87.2% ± 5.7% 0.015
D SH-SY5Y	WT	(100%)	vs.	SH-SY5Y	APP−/− 51.6% ± 3.3% 0.002
SH-SY5Y	WT	(100%)	vs.	SH-SY5Y	+	APP695 169.9% ± 29.4% 0.005
E MEF	APP/APLP2−/−	(100%)	vs.	MEF	APP/
APLP2−/−	+	APP695
131.6% ± 6.9% 0.047
MEF	APP/APLP2−/−	(100%)	vs.	MEF	APP/
APLP2−/−	+	APP751
134.0% ± 6.9% 0.022
MEF	APP/APLP2−/−	(100%)	vs.	MEF	APP/
APLP2−/−	+	APP770
134.5% ± 4.4% 0.018
MEF	APP/APLP2−/−	(100%)	vs.	MEF	WT 186.6% ± 14.5% 0.000
Figure 4 IDE	gene	expression
A MEF	APPΔCT15	control	(100%)	vs.	MEF	APPΔCT15	+	C50 131.4% ± 11.6% 0.005
MEF	APPΔCT15	control	(100%)	vs.	MEF	APPΔCT15	+	AICD	
48 h
139.6% ± 10.2% 0.000
MEF	APPΔCT15	control	(100%)	vs.	MEF	APPΔCT15	+	AICD	
9d
145.4% ± 12.3% 0.000
B SH-SY5Y	control	(100%)	vs.	SH-SY5Y	+	C50 147.8% ± 10.4% 0.002
IDE	protein	level
C MEF	APPΔCT15	control	(100%)	vs.	MEF	APPΔCT15	+	C50 135.9% ± 6.4% 0.004
MEF	APPΔCT15	control	(100%)	vs.	MEF	APPΔCT15	+	AICD	
48 h
128.4% ± 8.5% 0.027
D MEF	PS1/2−/−	control	(100%)	vs.	MEF	PS1/2−/−	+	AICD	
(48	h)
135.9% ± 2.3% 0.000
Total Aβ-degradation: remaining Aβ
E MEF	PS1res	(100%)	vs.	MEF	PS1/2−/− 120.5% ± 3.2% 0.000
MEF	PS1res	(100%)	vs.	MEF	PS1/2−/−	+	C50 104.0% ± 4.2% 0.675
(Continues)
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in	MEF	APP/APLP2−/−:	143.0%	±	6.3%,	p	≤	0.001;	remaining	Aβ in 
MEF	APPΔCT15:	151.5%	±	8.2%,	p	≤	0.001)	(Figure	1c).	In	presence	
of	 insulin,	 acting	 as	 a	 competitive	 inhibitor	 for	 IDE	dependent	Aβ 





the	 NEP	 inhibitor	 thiorphan	 (Figure	 S4C).	 Notably,	 no	 significant	
alterations	between	MEF	WT	and	MEF	APP/APLP2−/−	 in	Aβ deg-
radation were observed in presence of both inhibitors, insulin and 
thiorphan	(Figure	S4D).
These	 results	 indicate	 that	 the	 PS-dependent	 APP	 cleavage	
product	AICD	might	also	be	involved	in	the	regulation	of	IDE	besides	
the	reported	influence	of	AICD	on	NEP	(Grimm	et	al.,	2015).
2.2  |  IDE enzyme activity and protein 
level are reduced in MEF cells devoid of PS1/2, APP/
APLP2, and AICD
In	 order	 to	 analyze	 whether	 the	 PS/APP/AICD-dependent	 effects	
on total Aβ-degradation	are	partially	based	on	an	altered	 IDE	activ-
ity,	we	measured	IDE	enzyme	activity	 in	MEF	PS1/2−/−,	MEF	APP/




Table	1).	As	 shown	 in	Figure	2c,d	 these	effects	 are	based	on	 a	 sig-
nificant	 reduction	of	 IDE	protein	 level.	 In	MEF	PS1/2−/−	cells	 lack-










2.3  |  Influence of PS, APP, and AICD on IDE gene 
expression in MEF and SH-SY5Y cells
AICD	has	been	reported	to	translocate	to	the	nucleus	and	to	be	
involved	 in	 the	 regulation	 of	 several	 target	 genes	 (Grimm	et	 al.,	
2015;	 Pardossi-Piquard	 et	 al.,	 2005;	 Robinson	 et	 al.,	 2014;	 von	
Rotz	et	al.,	2004).	To	examine	whether	the	reduction	of	IDE	pro-
tein	level	and	enzyme	activity	in	cells	devoid	of	PS,	APP,	or	AICD	
is caused by a decreased IDE	gene	expression	in	absence	of	AICD,	
we	performed	real-time	PCR	(RT-PCR)	analyses	of	the	correspond-
ing	cell	lines.	In	line	with	the	AICD-dependent	regulation	of	IDE by 
AICD,	IDE gene expression was found to be significantly reduced 
in	the	MEF	cells	lacking	PS1/2,	APP/APLP2,	or	the	APP	C-terminus	
(MEF	APPΔCT15)	(Figure	3a+b,	Table	1).	Next,	we	tested	whether	
the	AICD-dependent	transcriptional	regulation	of	IDE is restricted 
to	MEF	 cells.	 Considering	 the	 important	 Aβ-degrading function 
of	 IDE	 in	human	brain,	we	decided	to	use	the	human	neuroblas-
toma	 cell	 line	 SH-SY5Y	 as	 a	 second	 cellular	 model.	 In	 line	 with	
the	 findings	 obtained	 in	 the	 different	 MEF	 cell	 lines,	 IDE gene 
expression	was	 significantly	 reduced	 in	 SH-SY5Y	cells	 devoid	of	
p-Value
Figure 5 IDE	promoter	activity
A MEF	WT	(100%)	vs.	MEF	APP/APLP2−/− 32.2% ± 2.3% 0.004
MEF	WT	(100%)	vs.	MEF	APPΔCT15 57.5% ± 2.4% 0.001
B MEF	APPΔCT15	control	(100%)	vs.	MEF	APPΔCT15	+	C50 125.7% ± 4.1% 0.003
Figure 6 IDE	gene	expression
A Brain	WT	mice	(100%)	vs.	brain	APP−/−	mice 86.9% ± 4.8% 0.014
Brain	WT	mice	(100%)	vs.	brain	APPΔCT15+/−	mice 91.7% ± 2.9% 0.007
IDE	protein	level
B Brain	WT	mice	(100%)	vs.	brain	APPΔCT15+/−	mice 77.3% ± 4.9% 0.041
Correlation	IDE/APP gene expression
C Cohort	1	(Braak	stages	4–6) r = 0.455 0.000
D Cohort	2	(Braak	stages	1–3) r = 0.261 0.033
Figure	S4 Total Aβ-degradation: remaining Aβ
A MEF	WT	(100%)	vs.	MEF	APP/APLP2−/− 143.0% ± 6.3% 0.000
B MEF	WT	(100%)	vs.	MEF	APP/APLP2−/− 114.4% ± 3.1% 0.006
C MEF	WT	(100%)	vs.	MEF	APP/APLP2−/− 117.3% ± 4.3% 0.035
D MEF	WT	(100%)	vs.	MEF	APP/APLP2−/− 104.5% ± 7.7% 0.686
TA B L E  1 (Continued)
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PS1	 (SH-SY5Y	PS1−/−)	 (Figure	3c,	 Table	 1,	 cell	 line	 controlled	 in	
Figure	S2H)	or	APP	(SH-SY5Y	APP−/−)	(Figure	3d,	Table	1,	cell	line	
controlled	in	Figure	S2G).	 In	accordance	on	the	other	hand	over-
expression of APP695, the most common APP isoform in neuronal 
cells resulted in a significantly increased IDE gene expression in 




of different APP isoforms on IDE	gene	expression.	Therefore,	MEF	
APP/APLP2−/−	cells	were	transiently	retransfected	with	plasmids	
encoding for APP695, APP751, and APP770, the three major splice 
isoforms of APP. The levels of APP expression were significantly 
increased	 in	 all	 isoform-expressing	 cells	 compared	 to	 the	mock-
transfected	control	cells	(Figure	S2F).	All	three	APP	isoforms	up-
regulated IDE gene expression to a similar extent compared to 
mock-transfected	 MEF	 APP/APLP2−/−	 control	 cells	 (Figure	 3e,	
Table	1),	but	did	not	reach	the	level	of	MEF	WT	cells.
2.4  |  Impact of AICD on IDE gene expression and 
IDE protein level
To	further	strengthen	the	importance	of	AICD	in	the	regulation	of	IDE	






incubation	with	AICD	peptides	 also	 revealed	 a	 significant	 increase	 in	
IDE	 gene	 expression	 to	 139.6%	 and	 145.4%,	 respectively	 (Figure	 4a,	
Table	1).	Taking	into	consideration	that	both	incubation	times	showed	
comparable	effects	and	in	order	to	save	AICD,	only	the	short-term	in-




observed elevation of IDE	gene	expression	by	addition	of	AICD	peptides	






protein	 level	 after	 transient	 transfection	with	C50	or	 incubation	with	
AICD	peptides,	the	impaired	Aβ	degradation	found	for	MEF	PS1/2−/−	
(Figure	 1a)	 could	 be	 rescued	 by	 transient	 transfection	 with	 C50.	 A	
transient	 transfection	 of	 PS1/2−/−	with	 C50	was	 able	 to	 rescue	 the	
Aβ	degradation,	so	that	no	significant	difference	between	MEF	PS1res	
and	MEF	PS1/2−/−	C50	transfected	cells	could	be	observed.	Notably,	
compared	to	MEF	PS1/2−/−	remaining	Aβ peptides were significantly 
reduced	in	PS-deficient	MEF	transfected	with	C50	(Figure	4e,	Table	1).
2.5  |  The effect of a functional AICD domain on 
IDE promoter activity
Next,	 we	 analyzed	 whether	 IDE	 promoter	 activity	 is	 affected	
in	 cells	 lacking	 the	APP	protein	 family	 or	 a	 functional	AICD	do-
main. Therefore, cells were transiently transfected with the dual 
reporter	 system	 vector	 pEZX-PG04-IDE-Gluc.	 The	 Gaussia lu-




Table	 1),	 indicating	 that	 AICD	 regulates	 the	 promoter	 region	 of	
the	 IDE	coding	 sequence.	Consistent	with	 the	other	C50	 rescue	
experiments,	MEF	APPΔCT15	transfected	with	C50	showed	a	sig-
nificant	 increase	 in	 IDE	promoter	 activity	 to	 125.7%	 (Figure	 5b,	
Table	1).




last	 15	 aa	of	 the	C-terminus	 (APPΔCT15+/−),	 to	 validate	our	 find-
ings	 in	vivo.	Brain	homogenates	of	APP−/−	mice	 showed	a	 signifi-
cant reduction in IDE	gene	expression	(Figure	6a,	Table	1).	Similarly,	
IDE gene expression was significantly reduced in brain homogenates 
of APPΔCT15	expressing	heterozygous	transgenic	mice	(Figure	6a,	
Table	1).	IDE	protein	level	was	also	found	to	be	significantly	reduced	
in brain homogenates of APPΔCT15+/−	mice	(Figure	6b,	Table	1).
To	 further	 investigate	 the	 in	 vivo	 relevance	 of	 an	 AICD-
dependent upregulation of IDE	gene	expression,	we	analyzed	IDE as 
well as APP gene transcription in human postmortem brains of 156 
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AD affected individuals. APP gene expression positively correlated 
with IDE	gene	expression	 (r	=	0.455)	 in	patients	with	Braak	stages	
4–6	 (Figure	6c),	 representing	 the	 later	 stages	 in	AD.	Notably,	 this	
correlation	was	 highly	 significant	 (p	 ≤	 0.001),	 suggesting	 that	 our	
findings are not limited to cell culture or in vitro experiments. Also 
for	patients	with	Braak	stages	1–3	(67	patients)	we	found	a	positive	
significant correlation of IDE gene expression with APP gene expres-
sion	(Figure	6d).	The	combination	of	both	cohorts	(Braak	stages	1–6)	
revealed a significant positive correlation for IDE and APP gene ex-
pression	 (Figure	S5A).	 In	 accordance	 to	 the	positive	correlation	of	
IDE with APP gene expression we also found a significant positive 
correlation	 for	 the	 protein	 level	 of	 IDE	with	APP	 (Figure	 S5B)	 for	
samples	 (Braak	1–6)	where	 enough	 amount	 of	 protein	 to	 perform	
Western	blots	were	available.
No significant alterations in IDE and APP gene expression were 
observed	 for	Braak	stages	2–6	compared	 to	Braak	stage	1,	 repre-
senting	 early	 AD	 (Figure	 S5C).	 Similarly,	 amyloid	 burden	 did	 not	
influence IDE and APP	 gene	expression	 (Figure	S5D).	 The	positive	
correlation between IDE and APP gene expression is not dependent 
on the gender as we obtained a significant positive correlation for 
both,	 women	 and	 men	 (Figure	 S5F).	 The	 ApoE	 status	 of	 the	 pa-
tients had no impact on APP and IDE	gene	expression	(Figure	S5E).	
Additionally, no significant correlations were obtained for age and 
postmortem	delay	(Figure	S5G,H).
3  |  DISCUSSION
Extracellular	 senile	 plaques	 composed	 of	 aggregated	 Aβ peptides 
are	one	of	 the	main	pathological	hallmarks	of	AD,	however,	oligo-
meric forms of Aβ seem to be the primary toxic species causing 
synaptic	 damage	 and	 neurodegeneration	 (Lambert	 et	 al.,	 1998;	
Umeda	et	al.,	2011)	and	levels	of	soluble	Aβ strongly correlate with 
markers	of	AD	severity	 (McLean	et	al.,	1999).	Soluble	extracellular	
Aβ peptides in the brain can be removed by efflux into the blood 
via	the	blood-brain	barrier	(Tarasoff-Conway	et	al.,	2015)	or	can	be	
F I G U R E  3 IDE	gene	expression	determined	by	RT-PCR	in	different	cell	lines	devoid	of	the	catalytically	active	components	of	the	
γ-secretase	complex,	the	APP	family	or	AICD	and	in	APP	overexpressing	cell	lines.	(a)	IDE gene expression in mouse embryonic fibroblasts 
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degraded	among	others	by	 IDE	or	NEP,	which	play	also	an	 impor-
tant role in intracellular Aβ-degradation	(Iwata	et	al.,	2001;	Stargardt	
et	al.,	2013).	NEP	levels	have	been	found	to	be	reduced	in	hippocam-




2010;	Wang	 et	 al.,	 2010)	 or	 increased	 IDE	 activity	 (Miners	 et	 al.,	
2009;	Morelli	et	al.,	2004).	Recently,	we	and	others	could	show	an	
AICD-dependent	regulation	of	NEP	increasing	its	gene	expression,	
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protein	level,	and	activity	(Belyaev	et	al.,	2009,	2010;	Grimm	et	al.,	
2015;	Pardossi-Piquard	et	 al.,	 2005;	Xu	et	 al.,	 2011).	 In	our	previ-
ous	study,	we	could	 show	that	an	AICD-dependent	change	 in	Aβ-
degradation	 could	only	be	partially	 rescued	by	utilizing	 thiorphan,	
a specific inhibitor of NEP. These results suggest that beside NEP 
another Aβ-degrading	 protease	 might	 be	 also	 regulated	 by	 AICD	
(Grimm	 et	 al.,	 2015),	 which	 is	 in	 line	with	 our	 recent	 finding	 that	
thiorphan could only partially attenuate the difference between 
MEF	WT	and	MEF	APP/APLP2−/−	cells	in	respect	to	Aβ degradation.
In	the	present	study,	we	identified	IDE as a further target gene of 
AICD	using	both	cells	devoid	of	AICD	or	AICD	generation	and	AICD	
overexpressing	 cells.	We	 found	 IDE gene expression to be consis-
tently	downregulated	in	cells	with	impaired	AICD	generation	(MEF	
PS1/2−/−;	SH-SY5Y	PS1−/−),	devoid	of	APP	or	the	APP	protein	fam-
ily	 (MEF	APP/APLP2−/−,	 SH-SY5Y	APP−/−)	 or	 lacking	 a	 functional	
AICD	domain	 (MEF	APPΔCT15).	mRNA	 levels	 of	 IDE were signifi-
cantly	downregulated	in	mouse	embryonic	fibroblasts	knocked	out	
for both catalytically active subunits of the γ-secretase complex, 
PS1	and	PS2.	In	line,	IDE gene expression was also significantly re-
duced	 in	 human	neuroblastoma	PS1	 knockout	 cells.	 Likely	 caused	
by	 the	 remaining	 expression	 of	 PS2	 in	 this	 cell	 line,	 the	 observed	
effect strength on IDE mRNA level was not as pronounced as for 
PS1/2	lacking	MEF	cells.	Due	to	the	high	number	of	substrates	that	
can be cleaved by the γ-secretase	complex	 (Wolfe,	2020),	we	ver-







to interact with the adaptor protein FE65, increasing the stability of 
AICD	(Kimberly	et	al.,	2001)	and	enabling	the	transport	of	AICD	to	
the nucleus where it associates with Tip60 leading to the formation 
of	the	AFT-complex	(Goodger	et	al.,	2009;	von	Rotz	et	al.,	2004).
In	 line	 with	 reduced	 IDE	 gene	 expression	 obtained	 for	 AICD	
deficient cells, we observed elevated IDE gene expression in cells 
overexpressing	APP	or	the	AICD	encoding	fragment	C50	and	in	cells	
incubated	with	AICD	peptides.	 IDE mRNA levels were significantly 
elevated in human neuroblastoma cells stably expressing APP695. 
Moreover,	we	observed	no	differences	with	respect	to	the	expressed	
main APP isoforms, neuronal APP695 and non-neuronal APP751 and 
APP770. APP695, APP751 and APP770 expressed in mouse embry-
onic fibroblasts devoid of the APP family, showed a nearly identical 
increase in IDE	gene	expression	compared	to	APP/APLP2	knockout	
cells.	However,	the	IDE gene expression level did not reach the level 
of	WT	fibroblasts,	which	showed	an	even	stronger	 increase	 in	 IDE 
mRNA level. This might be caused by the endogenous expression of 
APLP2	 in	WT	fibroblasts,	resulting	 in	the	γ-secretase derived frag-
ment	of	APLP2	(ALID2).	It	cannot	be	excluded	that	ALID2	might	also	
be involved in the regulation of IDE gene expression as it has been 
reported	that	ALID2	influences	the	expression	of	the	Aβ-degrading 
enzyme	NEP.	Fibroblasts	 lacking	APLP2	revealed	reduced	NEP ex-
pression and activity and NEP activity could be restored by retrans-
fection	with	 APLP2	 (Pardossi-Piquard	 et	 al.,	 2005).	 Beside	 ALID2	
it has been shown that the γ-secretase	cleavage	product	of	APLP1	
(ALID1)	 increases	NEP	activity	 (Pardossi-Piquard	et	al.,	2005).	The	
impact	 of	 ALID1	 and	 ALID2	 on	 IDE gene transcription has to be 
addressed	in	further	studies.	In	contrast	to	our	finding	that	all	APP	
isoforms affected IDE	mRNA	levels,	Nalivaeva	et	al.	(2016)	reported	
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increased IDE gene expression for APP751 and APP770 overex-
pressing cells but not for cells overexpressing APP695. These diver-
gent findings might be caused by the level of APP overexpression 
or	 the	analyzed	cell	 line	and	 the	 impact	of	different	APP	 isoforms	
on IDE gene transcription could be addressed in siRNA experiments 
silencing only one APP splice isoform.
Further	 illustrating	 an	 AICD-dependent	 regulation	 of	 IDE	 we	
found IDE	gene	expression	to	be	significantly	increased	in	SH-SY5Y	





(c)	Correlation	of	APP/IDE gene expression in human postmortem	brains	of	156	patients	diagnosed	with	Braak	stages	4–6.	(d)	Correlation	of	
APP/IDE gene expression in human postmortem	brains	of	67	patients	diagnosed	with	Braak	stages	1–3.	Statistical	significance	was	calculated	
as	described	in	Table	S3.	(e)	Schematic	overview	of	the	proposed	feedback	cycles	for	AICD-dependent	IDE	regulation	and	AICD-dependent	
APP processing
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cells	 stably	 expressing	 C50,	 encoding	 the	AICD	 fragment	 of	 APP.	
Similarly,	fibroblasts	lacking	a	functional	AICD	domain	significantly	
increased IDE	gene	expression	when	transfected	with	the	C50	plas-







production.	 Importantly,	 no	 statistical	 difference	was	 observed	 in	
the	protein	levels	of	IDE	in	cells	devoid	of	PS1/2	or	WT	fibroblasts	
incubated with the γ-secretase inhibitor DAPT. Also, fibroblasts 
lacking	the	APP	family	or	lacking	a	functional	AICD	domain	consis-
tently	showed	reduced	IDE	protein	levels,	resulting	in	a	reduced	IDE	
activity and impaired Aβ-degradation as expected by the described 
AICD-dependent	regulation	of	 IDE gene expression. A possible di-
rect	impact	of	AICD	on	IDE	promoter	activity	could	be	proposed	by	








that	 AICD	 upregulates	 the	 expression	 of	 the	 peroxisome	 prolifera-
tor-activated receptor γ coactivator-1α	 (PGC-1α)	 (Robinson	 et	 al.,	
2014)	resulting	 in	PPARγ	activation,	one	might	hypothesize	that	the	
AICD-dependent	upregulation	of	IDE	found	in	the	present	study	could	
be mediated by the PPARγ	pathway.	Interestingly,	Du	et	al.	(2009)	re-
ported that PPARγ plays an important role in regulating IDE expres-
sion in rat primary neurons through binding to a functional peroxisome 
proliferator-response	element	(PPRE)	in	the	IDE	promoter,	promoting	
IDE	gene	transcription.	 In	vivo,	the	PPARγ	activator	rosiglitazone	in-
creased the expression level of IDE and decreased Aβ levels in a mixed 
mouse model of AD and type 2 diabetes and alleviated the spatial 
learning	and	recognition	 impairments	 in	 these	mice	 (Li	et	al.,	2018).	
Additionally, inhibition of PPARγ by injecting the PPARγ antagonist 
GW9662	in	the	fourth	ventricle	of	APP/PS1	transgenic	mice	markedly	
decreased	cerebellar	levels	of	IDE	and	significantly	induced	Aβ levels 
(Du	et	al.,	2009).	 In	 line	with	our	hypothesis	 that	PGC-1α might be 
involved in the regulation of IDE	gene	transcription,	Leal	et	al.	(2013)	
reported a significant increase in cytosolic and mitochondrial levels of 





form was found in non-demented brains, whereas this correlation was 
weaker	in	AD	brains	(Leal	et	al.,	2013).	The	postulated	AICD/PGC-1α/
PPARγ involvement in IDE transcriptional regulation might also play a 
role in the transcriptional regulation of NEP as it has been shown, that 
activation	of	the	nuclear	retinoid	X	receptor	(RXR),	the	heterodimeric	
partner of PPARγ,	upregulates	not	only	IDE	but	also	the	Aβ degrading 
enzyme	NEP	(Nalivaeva	et	al.,	2016).	In	the	present	study,	we	found	
some	 indications	 that	 the	AICD/PGC-1α/PPARγ pathway might in-
deed	be	 involved	 in	 the	 regulation	of	 IDE.	PGC-1α gene expression 
is	significantly	downregulated	in	SH-SY5Y	WT	cells	incubated	with	a	
γ-secretase	inhibitor	and	thus	devoid	of	AICD	generation	(Figure	S6A)	




ence of a PPARγ inhibitor is significantly less pronounced than without 
inhibitor	(Figure	S6C)	indicating	the	involvement	of	the	PPARγ path-
way	in	the	regulation	of	IDE.	Similarly,	the	effect	strength	on	IDE gene 
expression	was	 less	 pronounced	 in	 presence	 of	 a	 PGC-1α-inhibitor 
(Figure	S6B).	Although	our	data	are	in	line	with	the	models	discussed	
in literature, further studies have to clarify the involvement of the 
PGC-1α/PPARγ	pathway	in	the	regulation	of	IDE.
The in vivo relevance of our findings was assessed in APP 
knockout	mouse	 brains	 and	 brains	 of	 heterozygous	mice	 express-
ing	 a	 construct	 lacking	 a	 functional	 AICD	 domain.	 Brain	 homoge-
nates of these mouse models revealed reduced IDE mRNA levels. 
Furthermore, we found a strong positive correlation of APP mRNA 
levels with IDE mRNA levels in postmortem brains of 223 patients in 
two	cohorts	(Braak	stages	1–3	and	Braak	stages	4–6).	Also,	the	IDE	
protein level correlated with the APP protein level in patients with 
Braak	stages	1–6.
However,	although	the	data	of	human	postmortem brain tissue 
is in line with the other experimental data, it has to be empha-
sized	 that	 this	 data	 has	 to	 be	 interpreted	 carefully.	 The	 average	
postmortem	 time	 of	 06:07	 hours	 and	 the	 short	 half-life	 of	 AICD	




In	 summary,	 we	 propose	 a	 feedback	 cycle	 for	 the	 AICD-
dependent	 regulation	 of	 IDE,	 in	 which	 AICD	 increases	 its	 own	
degradation	as	IDE	has	been	also	found	to	degrade	AICD	peptides	
(Edbauer	et	al.,	2002).	AICD	upregulates	IDE gene expression, ei-
ther	direct	or	by	the	above-discussed	involvement	of	the	PGC-1α/
PPARγ	pathway	leading	to	increased	IDE	protein	level	and	activity	
(Figure	 6e).	 The	 increased	 IDE	 activity,	 in	 return,	 results	 in	 ele-
vated degradation of Aβ	as	well	as	AICD	peptides,	resulting	in	the	
proposed	feedback	cycle.	This	cycle	is	closely	linked	to	a	feedback	
mechanism proposed for Aβ	 generation	 and	 degradation.	 AICD	
decreases APP processing by downregulating the expression of 
WASP-family	 verprolin	 homologous	 protein	1	 (WASF1),	 resulting	
in	 impaired	 budding	 of	 APP	 containing	 vesicles	 from	 the	 Golgi-
apparatus, thereby reducing cell-surface APP and Aβ generation 
(Ceglia	et	al.,	2015).
For the understanding of the disease mechanism, it should be 
taken	 into	 consideration	 that	APP	processing	 and	 therefore	Aβ 
production is a continuous ongoing process under physiological 
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conditions.	Obviously,	to	achieve	a	homeostasis	where	no	accu-
mulation of Aβ	 takes	place,	Aβ-degradation and production has 
to	be	tightly	regulated.	Our	paper	might	help	to	understand	that	
this	 regulation	encompasses	AICD	as	 a	 pivotal	 element	both	 in	
regulating Aβ-degradation and Aβ production and importantly 
also	 in	 regulating	 its	own	degradation.	Under	pathological	 con-
ditions, the disturbance of these complex entangled cycles leads 
to an accumulation of Aβ and promotes the progression of the 
disease.
4  |  E XPERIMENTAL PROCEDURES
4.1  |  Chemicals and reagents
All	chemicals	and	reagents	were	obtained	from	Merck	former	Sigma-
Aldrich if not stated otherwise.
4.2  |  Cell culture, mouse and human brain samples
Different	MEF	 and	 human	 neuroblastoma	 cells	 (SH-SY5Y)	 were	
used	for	cell-based	experiments.	MEF	WT,	MEF	lacking	both	PS1	
and	 PS2	 (MEF	 PS1/2−/−),	 APP/ALPL2	 deficient	MEF	 (MEF	APP/
APLP2−/−)	 and	MEF	expressing	 a	 truncated	APP	 construct	 lack-
ing	 the	 last	 15	 C-terminal	 aa	 (MEF	 APPΔCT15)	 were	 cultivated	
in	Dulcecco’s	Modified	Eagle’s	Medium	 (DMEM)	 containing	10%	
fetal	 calf	 serum	 (FCS;	PAN-Biotech).	For	MEF	PS1/2−/−	cells	 re-
transfected	with	PS1	 (MEF	PS1res)	 (Grimm	et	al.,	2005)	 the	cul-
ture medium additionally contained 300 μg/ml	 Zeocin	 (Fisher	
Scientific).	SH-SY5Y	WT,	SH-SY5Y	lacking	PS1	(SH-SY5Y	PS1−/−)	
or	APP	(SH-SY5Y	APP−/−)	due	to	clustered	regularly	 interspaced	
short	 palindromic	 repeats	 (CRISPR)/CRISPR	 associated	 (Cas)	
mediated	 knockout	 (see	 below)	were	maintained	 in	DMEM/10%	








provided	 by	 Prof.	 U.	Müller	 (Institute	 of	 Pharmacy	 and	Molecular	
Biotechnology,	University	of	Heidelberg,	Germany).
For the ex vivo gene expression analysis we used two cohorts of 
human AD postmortem brain samples dissected from the prefron-
tal	cortex	and	provided	by	The	Netherland	Brain	Bank	(Netherlands	
Institute	for	Neuroscience,	Amsterdam,	The	Netherlands;	NBB).	The	
first cohort includes 121 female and 35 male brain samples with an 
average postmortem	 delay	 of	 06:06	 hours	 and	 Braak	 stages	 4–6.	
The second one includes 36 female and 31 male brain samples with 
Braak	stages	1–3	and	an	average	postmortem delay of 06:10 hours 
(see	Table	S1).




(PX459)	 plasmid	 was	 performed	 according	 to	 Ran	 and	 colleagues	
(Ran	et	al.,	2013).	A	detailed	description	can	be	found	in	supporting	
information.
4.4  |  Treatment of cells with inhibitors and 
AICD peptides
Incubation	 of	 cells	 with	 γ-secretase	 inhibitor	 DAPT	 (2.5	 μM)	 and	
γ-secretase	 inhibitor	 X	 (2	 µM)	 or	 the	 corresponding	 solvent	 con-
trol	DMSO	was	carried	out	for	48	h	(24	h	+	24	h)	in	DMEM	culture	
medium	containing	1%	FCS.	PPARγ-inhibitor	GW9662	(10	µM)	and	
PGC-1α-inhibitor	 SR-18292	 (20	 µM)	 or	 DMSO	 as	 solvent	 control	
were	incubated	for	16	h	(4	h	+	12	h)	 in	DMEM	containing	1%	FCS.	
For 48 h incubation of cells with 2.5 μM	 synthetic	 AICD	 peptide	
(KMQQNGYENPTYKFFEQMQN;	Genscript)	or	the	solvent	H2O	we	
used	Saint-PhD	protein	transfection	reagent	(Synvolux	Therapeutics)	





4.5  |  Lactate dehydrogenase (LDH) activity assay




4.6  |  Transfection of cells with plasmid DNA
Lipofectamine®	 2000	 Transfection	 Reagent	 (Fisher	 Scientific)	 and	
Opti-MEM	(Invitrogen)	were	used	according	to	manufacturer's	pro-
tocol for transfections.
For overexpression of the different APP isoforms the following vec-
tors were used: pcDNA™3.1/Zeo(+) APP695, pcDNA™3.1/Zeo(+) APP751, 
and pcDNA™3.1/Zeo(+) APP770. They were applied to confluent cells 
on 6-well plates and further analysis was performed 48 h afterward.
For promoter activity assays confluent cells on 24-well plates 
were	transfected	with	the	dual	reporter	system	vector	pEZX-PG04-
IDE-GLuc	(GeneCopoeia)	24	h	prior	to	further	analysis.
MEF	 cells	 were	 transfected	 with	 SureSilencing™-Insulin-
degrading	enzyme	shRNA	plasmids	(SABioscience)	according	to	the	
manufacturer	 for	 IDE-KD	analysis.	 Further	experiments	were	per-
formed 24 h after transfection.
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4.7  |  Protein concentration
Bicinchoninic acid assay was used for determination of the protein 
concentrations	 in	 samples	 according	 to	 Smith	 et	 al.	 (1985)	 as	 de-
scribed in detail earlier. Prior to their use in experiments, samples 
were	adjusted	to	equal	protein	amounts.
4.8  |  Total Aβ-degradation
Degradation of total Aβ	 in	 different	MEF	 cell	 lines	was	performed	
according	to	Grimm	et	al.	(2016)	as	described	in	detail	in	supporting	
information.
4.9  |  Western blot experiments
For	examination	of	IDE	protein	level,	cell	lysates	were	prepared	as	
described	above.	Lysis	buffer	was	additionally	supplemented	with	
Complete	 protease	 inhibitor	 cocktail	 (Roche	 Diagnostics).	 After	
centrifugation of the lysates for 5 min at 13,000 g	 and	 4°C	 the	
supernatants	were	adjusted	 to	equal	protein	amounts	and	 loaded	
on	10–20%	tris-tricine-gradient	gels	(Anamed	Elektrophorese)	and	
proteins were transferred onto nitrocellulose membranes afterward 
(Whatman).	A	detailed	description	of	Western	blot	analysis	includ-














4.12  |  RT-PCR experiments
For	gene	expression	analysis	quantitative	real-time	(RT)	polymerase	
chain	reaction	(PCR)	was	performed	and	results	were	normalized	to	
β-actin and changes in expression were calculated using the 2−(ΔΔCt) 
method	 (Livak	&	Schmittgen,	2001).	A	detailed	description	can	be	
found in supporting information.
4.13  |  Data analysis
The	quantified	data	 represent	an	average	of	at	 least	 five	 independ-
ent experiments for each cell culture experiment. 223 human brain 
samples	were	analyzed.	For	APP−/−	mice	four	brain	samples	and	for	
APPΔCT15	 eight	 brain	 samples	 derived	 from	 different	 mice	 were	
analyzed.	Error	bars	represent	the	standard	error	of	the	mean.	Prior	
to	calculating	statistical	 significance,	 it	was	checked	 if	data	are	nor-
mally	 distributed	 via	 Shapiro–Wilk-test	 and	 Levene's	 test	 whether	
homogeneity	of	 variances	 could	be	assumed.	 If	 data	were	normally	
distributed and variances were homogeneous, statistical significance 
was	calculated	via	analysis	of	variances	test	(ANOVA).	If	the	assump-





was	 obtained.	 After	 a	 significant	 difference	 in	 ANOVA,	 we	 either	
used	 two-sided	Dunnett	 post	 hoc	 test,	 or	 Tukey-HSD,	 to	 calculate	
statistical	differences	between	groups,	for	Welch's	test	we	used	the	
Games–Howell	post	hoc	test.	For	the	statistical	analysis	of	the	human	
brain samples, we assumed that the data were normally distributed, 
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